Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
Systemic treatments for metastatic cutaneous melanoma
S Pasquali, AV Hadjinicolaou, VC Sileni… - Cochrane Database …, 2018 - cochranelibrary.com
Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …
From genes to drugs: targeted strategies for melanoma
KT Flaherty, FS Hodi, DE Fisher - Nature Reviews Cancer, 2012 - nature.com
The past decade has revealed that melanoma is comprised of multiple subclasses that can
be categorized on the basis of key features, including the clinical stage of disease, the …
be categorized on the basis of key features, including the clinical stage of disease, the …
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
The VEGF pathway in cancer and disease: responses, resistance, and the path forward
Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago.
Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate …
Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate …
Interferon alpha for the adjuvant treatment of cutaneous melanoma
S Mocellin, MB Lens, S Pasquali… - … of systematic reviews, 2013 - cochranelibrary.com
Background Interferon alpha is the only agent approved for the postoperative adjuvant
treatment of high‐risk cutaneous melanoma. However, the survival advantage associated …
treatment of high‐risk cutaneous melanoma. However, the survival advantage associated …
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Vascular endothelial growth factor (VEGF) has been confirmed as an important therapeutic
target in randomised clinical trials in multiple disease settings. However, the extent to which …
target in randomised clinical trials in multiple disease settings. However, the extent to which …
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated …
KB Kim, JA Sosman, JP Fruehauf, GP Linette… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of
vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo …
vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo …
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
Background: Current therapies for metastatic melanoma are targeted either at cancer
mutations driving growth (eg, vemurafenib) or immune-based therapies (eg, ipilimumab) …
mutations driving growth (eg, vemurafenib) or immune-based therapies (eg, ipilimumab) …
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …
cancer treatment and each is associated with unique benefits and limitations. Both types of …